Mereo BiopharmaMREO.OValuation Analysis

As of Oct 16, 2026, Mereo Biopharma (MREO.O) trades at a negative P/E (-1.72x, due to a recent net loss), P/B of 1.69x, P/S of N/A, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 40th percentile over the trailing 10Y window (vs. 22nd percentile over 3Y); P/S historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data).
Cross-sectional valuation: its P/B ranks at the 40th percentile within its industry and the 53rd percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
Relative to industry peers, its P/B shows a deeper discount than it does against the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Mereo Biopharma operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.